Tourmaline Bio (TRML) Stock Price, News & Analysis

Company Overview

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Key Stats

• Today's Range: $47.98 to $47.98
• 50-Day Range: $47.74 to $48.16
• 52-Week Range: $13.27 to $48.27
• Volume: N/A
• Average Volume: 592,710 shs
• Market Capitalization: $1.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.94
• Consensus Rating: Hold

Tourmaline Bio Stock Analysis - MarketRank™

Tourmaline Bio scored higher than 1% of companies evaluated by MarketBeat, and ranked 852nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Tourmaline Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 9 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Tourmaline Bio is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Tourmaline Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tourmaline Bio is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tourmaline Bio is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tourmaline Bio has a P/B Ratio of 4.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TRML.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tourmaline Bio does not currently pay a dividend.

Dividend Growth

Tourmaline Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for TRML on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRML Stock Analysis - Frequently Asked Questions

How were Tourmaline Bio's earnings last quarter?

Tourmaline Bio, Inc. (NASDAQ:TRML) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.04.

When did Tourmaline Bio IPO?

Tourmaline Bio (TRML) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,825,000 shares at a price of $16.00-$18.00 per share.

What other stocks do shareholders of Tourmaline Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRML
• Previous Symbol: NASDAQ:TRML
• CIK: 1827506
• Web: N/A
• Phone: 502-398-9250
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tourmaline Bio: $47.94
• High Price Target: $48.00
• Low Price Target: $47.50
• Potential Upside/Downside: -0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.50%
• Return on Assets: -29.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.68
• Quick Ratio: 24.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.71 per share
• Price / Book: 4.10

Miscellaneous

• Outstanding Shares: 25,692,000
• Free Float: 22,352,000
• Market Cap: $1.23 billion
• Optionable: Optionable
• Beta: 2.27